<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084043</url>
  </required_header>
  <id_info>
    <org_study_id>Synchro-Neb</org_study_id>
    <nct_id>NCT02084043</nct_id>
  </id_info>
  <brief_title>In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation</brief_title>
  <acronym>Synchro-Neb</acronym>
  <official_title>In Vitro Comparison of Continuous and Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation: Analysis of Inhaled and Lost Doses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital St Luc, Brussels</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Applied Sciences of Western Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>School of Gestion and Engineering Vaud (HEIG-VD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital St Luc, Brussels</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using an adult lung bench model of non invasive ventilation, the aim of the study is to
      compare an experimental system of breath-synchronized vibrating mesh nebulizer to a
      conventional vibrating mesh nebulizer during non invasive ventilation in terms of inhaled
      and lost doses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Inhaled dose</measure>
    <time_frame>after 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The inhaled dose assessed by residual gravimetric method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expiratory wasted dose</measure>
    <time_frame>after 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The dose expelled in the ambient air through the exhalation port assessed by residual gravimetric method</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimated lost dose</measure>
    <time_frame>after 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The dose lost into the circuit (nebulizer included) assessed by residual gravimetric method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Respiratory Diseases</condition>
  <condition>Lung Diseases</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>COPD</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Breath-actuated vibrating mesh nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional vibrating mesh nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulization of Amikacin during NIV (RR: 15 cycles/minute)</intervention_name>
    <description>500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute</description>
    <arm_group_label>Breath-actuated vibrating mesh nebulizer</arm_group_label>
    <arm_group_label>Conventional vibrating mesh nebulizer</arm_group_label>
    <other_name>Amikacine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulization of Amikacin during NIV (RR: 25 cycles/minute)</intervention_name>
    <description>500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV  is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute</description>
    <arm_group_label>Breath-actuated vibrating mesh nebulizer</arm_group_label>
    <arm_group_label>Conventional vibrating mesh nebulizer</arm_group_label>
    <other_name>Amikacine sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not applicable (in vitro study)

        Exclusion Criteria:

          -  hypersensitivity (allergic) reactions to aminoglycosides
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Bernard Michotte, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Health Sciences (HESAV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Dugernier, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc, service des soins intensifs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Staderini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Gestion and Engineering Vaud (HEIG-VD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rares Rusu, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>School of Gestion and Engineering Vaud (HEIG-VD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Roeseler, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques universitaires Saint-Luc, service des soins intensifs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Liistro, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques universitaires Saint-Luc, service de pneumologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Reychler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cliniques universitaires Saint-Luc, service de pneumologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Bernard Michotte, PhD student</last_name>
    <email>jean-bernard.michotte@hesav.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grégory Reychler, PhD</last_name>
    <email>gregory.reychler@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Bernard Michotte, PhD student</last_name>
      <email>jean-bernard.michotte@hesav.ch</email>
    </contact>
    <contact_backup>
      <last_name>Gregory Reychler, PhD</last_name>
      <email>gregory.reychler@uclouvain.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Bernard Michotte, PhD student</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Dugernier, PhD student</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Reychler, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Health Sciences (HESAV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>School of Gestion and Engineering Vaud (HEIG-VD)</name>
      <address>
        <city>Yverdon-les-Bains</city>
        <zip>1401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>March 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Applied Sciences of Western Switzerland</investigator_affiliation>
    <investigator_full_name>Jean-Bernard Michotte</investigator_full_name>
    <investigator_title>MSc, PhD Student</investigator_title>
  </responsible_party>
  <keyword>aerosol delivery</keyword>
  <keyword>vibrating mesh nebulizer</keyword>
  <keyword>breath-actuated nebulizer</keyword>
  <keyword>non invasive ventilation</keyword>
  <keyword>bilevel ventilator</keyword>
  <keyword>single limb circuit ventilator</keyword>
  <keyword>Amikacin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
